Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of “Buy” by Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have received a consensus recommendation of “Buy” from the fifteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Fifteen analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have covered the stock in the last year is $40.60.

A number of research firms have recently commented on GH. JPMorgan Chase & Co. increased their target price on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Leerink Partners cut their price objective on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. The Goldman Sachs Group lifted their target price on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Sanford C. Bernstein cut their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th.

Insider Activity

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,432 shares of company stock valued at $175,423 in the last quarter. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Guardant Health

Hedge funds have recently modified their holdings of the company. Lord Abbett & CO. LLC bought a new position in shares of Guardant Health in the third quarter worth about $15,624,000. Exome Asset Management LLC boosted its stake in Guardant Health by 13.7% in the 3rd quarter. Exome Asset Management LLC now owns 89,800 shares of the company’s stock worth $2,060,000 after purchasing an additional 10,800 shares during the period. Geode Capital Management LLC grew its holdings in Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after buying an additional 29,686 shares in the last quarter. Pier Capital LLC raised its position in shares of Guardant Health by 36.7% during the third quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock valued at $3,634,000 after buying an additional 42,575 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Guardant Health by 188.6% in the third quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock worth $232,325,000 after buying an additional 6,618,785 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Trading Up 1.2 %

NASDAQ:GH opened at $36.59 on Friday. The firm has a market capitalization of $4.52 billion, a P/E ratio of -8.63 and a beta of 1.28. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. Guardant Health has a one year low of $15.81 and a one year high of $38.53. The company’s 50-day simple moving average is $32.34 and its 200 day simple moving average is $28.61.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The company had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.73) earnings per share. As a group, analysts forecast that Guardant Health will post -3.44 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.